DE GRUYTER Rev Environ Health 2016; aop

Corrigendum

Dominique Belpomme, Christine Campagnac and Philippe Irigaray*

Corrigendum to: Reliable disease biomarkers characterizing and identifying electrohypersensitivity and multiple chemical sensitivity as two etiopathogenic aspects of a unique pathological disorder

DOI 10.1515/reveh-2015-8888

Corrigendum to: Dominique Belpomme, Christine Campagnac and Philippe Irigaray. Reliable disease biomarkers characterizing and identifying electrohypersensitivity and multiple chemical sensitivity as two aspects of a unique pathological disorder. Reviews on Environmental Health 2015; volume 30, Issue 4, pp. 251-271. (DOI: 10.1515/ reveh-2015-0027):

Since the publication of the article, some typographic errors - have been discovered but without impact on the

content of the paper in Table 3: high-sensitivity C reactive protein (hs-CRP), immunoglobulin E (IgE), vitamin D2-D3 and histamine in the peripheral blood of EHS and/ or MCS self-reporting patients, in Table 4: protein S100B and nitrotyrosin (NTT) in the peripheral blood of EHS and/or MCS self-reporting patients, and in Table 5: HSP70 and HSP27 chaperone proteins and anti-O-myelin autoantibodies in the peripheral blood of EHS and/or MCS selfreporting patients.

The following provides the updated, corrected version of these tables. We apologize for any inconvenience caused.

^{*}Corresponding author: Philippe Irigaray, PhD, ARTAC, 57-59 rue de la convention, 75015 Paris, France, Phone: +33 (0)1 45 78 53 54, Fax: +33 (0)1 45 78 53 50, E-mail: philippei.artac@gmail.com; Association for Research and Treatments Against Cancer (ARTAC), F-75015 Paris, France; and European Cancer and Environment Research Institute (ECERI), Brussels, Belgium Dominique Belpomme: Paris V University Hospital, France; and

European Cancer and Environment Research Institute (ECERI), Brussels, Belgium

Christine Campagnac: Hospital Director, seconded from Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; and European Cancer and Environment Research Institute (ECERI), Brussels, Belgium

Table 3: High-sensitivity C reactive protein (hs-CRP), immunoglobulin E (lgE), vitamin D2-D3 and histamine in the peripheral blood of EHS and/or MCS self-reporting patients.

Patients groups	EHS	MCS	EHS/MCS
n	521	52	154
hs-CRP	78 (14.97%)	3 (5.77 %)	22 (14.2 9 %)
>3 mg/L	[3.27-51.91]	[3.5-10]	[3.27-21.61]
Vitamin D	33 (6.33%)	5 (9.62%)	16 (10.39%)
<10 ng/mL	[4.81-9.70]	[4.80-8.00]	[7.10-9.90]
Vitamin D	300 (57.58%)	25 (48.0 8 %)	92 (59.74%)
≥10 ng/mL and <30 ng/mL	[10.40-29.70]	[10.70-27.90]	[15.00-28.60]
Histamine	182/491 (37 .07 %)	18/44 (40.91 %)	59/142 (41.5 5 %)
>10 nmol/L	[10.08-360.00]	[10.80-90.00]	[10.10-1797.50]
IgE	115 (22.07%)	8 (15.38%)	38 (24.68%)
>100 UI/mL	[101-1387.60]	[131.10-294.87]	[103.30-1200.00]

Note that for each biomarker the range of values is indicated in square brackets, e.g. [minimum-maximum]. In bold, corrected or adjusted values.

Table 4: Protein S100B and nitrotyrosin (NTT) in the peripheral blood of EHS and/or MCS self-reporting patients.

Patients groups	EHS	MCS	EHS/MCS
n	521	52	154
S100B	73/495 (14.7%)	6/51 (11.8 %)	28/142 (19.7 %)
>0.105 µg/L	[0.105-2.090]	[0.110-0.500]	[0.110-0.470]
NTT	77/259 (29.7%)	6/29 (20.7 %)	22/76 (28.9%)
$>0.9 \mu g/mL$	[0.92-8.20]	[1.10-3.10]	[0.91-3.10]
Increased S100B and/or NTT	133/250 (53.2%)	12/22 (54.5%)	46/73 (63%)
Increased histamine, S100B and/or NTT	220/327 (67.3 %)	27/36 (75%)	91/125 (72.8 %)

Note that for each marker the range of values is indicated in square brackets, e.g. [minimum-maximum]. In bold, corrected or adjusted values.

Table 5: HSP70 and HSP27 chaperone proteins and anti-O-myelin autoantibodies in the peripheral blood of EHS and/or MCS self-reporting patients.

Patients groups	EHS	MCS	EHS/MCS
n	521	52	154
Hsp70	91/486 (18.7%)	4/52 (7.7%)	36/142 (25.4 %)
>5 ng/mL	[5.90-11.20]	[7.10-7.70]	[5.20-32.20]
Hsp27	123/476 (25.8%)	6/52 (11.5%)	42/132 (31.8 %)
>5 ng/mL	[5.20-11.20]	[5.90-9.20]	[5.10-25.00]
Hsp70 and/or Hsp27	162/487 (33.3%)	9/52 (17.3 %)	56/142 (39.4%)
Anti-O-myelin autoantibodies	109/477 (22.9 %)	8/47 (17%)	33/140 (23 .6 %)

Note that for each marker the range of values is indicated in square brackets, e.g. [minimum-maximum]. In bold, corrected or adjusted values.